¼¼°èÀÇ »þ¸£ÄÚ ¸¶¸® Åõ½ºº´ ½ÃÀå º¸°í¼­(2025³â)
Charcot-Marie-Tooth Disease Global Market Report 2025
»óǰÄÚµå : 1764281
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,993,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,765,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

»þ¸£ÄÚ ¸¶¸® Åõ½ºº´ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö 20.6%ÀÇ CAGR·Î 28¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº À¯Àü¼º ÁúȯÀÇ Á¶±â °ËÁø ÇÁ·Î±×·¥ ½ÃÇà, ½Å°æ ¹× ±ÙÀ° Àü¹® Ŭ¸®´ÐÀÇ È®´ë, Èñ±Í Áúȯ Ä¡·á¿¡ ´ëÇÑ »óȯ Á¤Ã¥ °³¼±, À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ º¸Çè Àû¿ë ¹üÀ§ È®´ë, ÀÇ·áºñ ÁöÃâ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ ±â°£ µ¿¾È ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Áúº´ º¯Çü Ä¡·áÁ¦ÀÇ ÀÓ»ó½ÃÇè ÁøÇà, À¯¸ÁÇÑ ½Å¾à Èĺ¸¹°ÁúÀÇ °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎ, Èñ±ÍÁúȯ Ä¡·á¿¡ ´ëÇÑ Á¦¾à»çÀÇ ÅõÀÚ È®´ë, ¿¬±¸°³¹ß Àμ¾Æ¼ºê¸¦ °­È­ÇÏ´Â Èñ±ÍÁúȯ Ä¡·áÁ¦ ÁöÁ¤, À¯ÀüÀÚ Ä¡·á ¹× À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ ¹ßÀü µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù.

ÇコÄɾî ÁöÃâÀÇ Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È »þ¸£ÄÚ-¸¶¸®-Åõ½º(CMT) Áúȯ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇコÄɾî ÁöÃâÀº ÀÇ·á ¼­ºñ½º, ¼Ò¸ðǰ, °Ç°­ À¯Áö ¹× °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃá Ȱµ¿¿¡ ´ëÇÑ ÃÑ ÁöÃâÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ ÁöÃâÀº ÷´Ü ÀÇ·á ±â¼úÀÇ ¹ßÀü°ú µµÀÔÀ¸·Î ÀÎÇØ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¿¬±¸, Àåºñ, Àü¹® ±³À°¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ Àüü ÀÇ·áºñ Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÇ·áºñ ÁöÃâ Áõ°¡´Â Àü¹® Ä¡·á, Áø´Ü µµ±¸, º¸Á¶ Ä¡·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í Áúº´ °ü¸®¸¦ °³¼±ÇÏ¿© CMT Ä¡·á¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 4¿ù ¿µ±¹ Á¤ºÎ ±â°üÀÎ Office for National Statistics´Â 2023-2024³â »çÀÌ ÀÇ·áºñ ÁöÃâÀÌ 6.5% Áõ°¡ÇÒ °ÍÀ̶ó°í º¸°íÇß½À´Ï´Ù. ÀÌó·³ ÀÇ·áºñ ÁöÃâÀÇ Áö¼ÓÀûÀÎ Áõ°¡´Â »þ¸£ÄÚ ¸¶¸® Åõ½ºº´ ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

»þ¸£ÄÚ ¸¶¸® Åõ½º(CMT) Áúȯ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº °£¿±Áٱ⼼Æ÷ Ä¡·á¿Í °°ÀÌ ´Ù¾çÇÑ Á¶Á÷ °ø±Þ¿øÀ¸·ÎºÎÅÍ ½±°Ô ºÐ¸® ¹× È®´ëÇÒ ¼ö Àִ ÷´Ü Ä¡·á¹ý °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. °£¿±Áٱ⼼Æ÷ Ä¡·á´Â ´Ù¾çÇÑ °Ç°­»óÅ¿¡¼­ Ä¡À¯¸¦ ÃËÁøÇÏ°í ¿°ÁõÀ» ¾ïÁ¦Çϱâ À§ÇØ ¿©·¯ Á¶Á÷ÇüÀ¸·Î ºÐÈ­ÇÒ ¼ö ÀÖ´Â ¸¸´É¼¼Æ÷¸¦ Ȱ¿ëÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 3¿ù Çѱ¹ÀÇ ¿£¼¿Àº ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ CMT Ä¡·á¿ë °£¿±Áٱ⼼Æ÷ Ä¡·áÁ¦ EN001ÀÌ Èñ±ÍÁúȯġ·áÁ¦(Èñ±ÍÀǾàǰ)·Î ÁöÁ¤µÇ¾ú´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ¸ñÀûÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. 1aÇü CMT ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ 1»ó ¿ÀÇ ¶óº§ ¿ë·® Áõ·® ÀÓ»ó½ÃÇè(NCT05333406)Àº 3+3 ½ÃÇè ¼³°è¿¡ µû¶ó 16ÁÖ µ¿¾È ¾ÈÀü¼º, ³»¾à¼º, ÃÖÀû ¿ë·®À» Æò°¡ÇÏ´Â 3+3 ½ÃÇè ¼³°è¿¡ µû¶ó ÁøÇàµÇ¾ú½À´Ï´Ù. Æò°¡µÇ¾ú½À´Ï´Ù. Àú¿ë·® ±×·ì Âü°¡Àڴ ù³¯ Á¤¸Æ Åõ¿©¸¦ ¹Þ¾Ò½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Charcot-marie-tooth (CMT) disease refers to a group of inherited neurological disorders that impact the peripheral nerves, which are responsible for muscle control and transmitting sensory information from the limbs to the brain. It is marked by progressive muscle weakness and atrophy, particularly in the feet, lower legs, hands, and forearms, often accompanied by sensory loss, foot deformities (such as high arches or hammertoes), and difficulty with walking. CMT is caused by genetic mutations that disrupt the structure or function of peripheral nerves. The condition usually begins during adolescence or early adulthood, though the age of onset and severity may differ among individuals.

The primary types of charcot-marie-tooth disease include CMT 1, CMT 2, CMT 3, and others. Type 1 CMT (CMT 1) is a hereditary neuropathy resulting from abnormalities in the myelin sheath that insulates peripheral nerves. Treatment involves various drug types, including nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors, tricyclic antidepressants, anticonvulsants, analgesics, and drugs currently in the pipeline. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The charcot-marie-tooth disease market research report is one of a series of new reports from The Business Research Company that provides charcot-marie-tooth disease market statistics, including charcot-marie-tooth disease industry global market size, regional shares, competitors with a charcot-marie-tooth disease market share, detailed charcot-marie-tooth disease market segments, market trends and opportunities, and any further data you may need to thrive in the charcot-marie-tooth disease industry. This charcot-marie-tooth disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The charcot-marie-tooth disease market size has grown exponentially in recent years. It will grow from $1.09 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 20.9%. Growth during the historic period can be attributed to rising public awareness of genetic neuropathies, increased utilization of genetic counseling services, greater physician education on rare diseases, strengthened patient advocacy initiatives, and broader access to neurophysiological testing.

The charcot-marie-tooth disease market size is expected to see exponential growth in the next few years. It will grow to $2.80 billion in 2029 at a compound annual growth rate (CAGR) of 20.6%. Growth in the forecast period can be attributed to the implementation of early screening programs for inherited disorders, the expansion of neurology and neuromuscular specialty clinics, improved reimbursement policies for rare disease treatments, broader insurance coverage for genetic testing, and increased healthcare spending. Key trends expected during this period include ongoing clinical trials for disease-modifying therapies, a strong pipeline of promising drug candidates, growing investment by pharmaceutical companies in rare disease treatments, orphan drug designations that enhance research and development incentives, and advancements in gene therapy and gene editing technologies.

The rise in healthcare expenditure is expected to drive the growth of the Charcot-Marie-Tooth (CMT) disease market in the coming years. Healthcare expenditure refers to the total spending on medical services, supplies, and activities focused on maintaining or improving health. This expenditure is increasing due to the advancement and adoption of cutting-edge medical technologies, which require significant investment in research, equipment, and specialized training-contributing to higher overall healthcare costs. The growth in healthcare spending facilitates greater investment in CMT treatment by enhancing access to specialized therapies, diagnostic tools, and supportive care services, leading to improved disease management. For example, in April 2025, the Office for National Statistics, a UK-based government agency, reported a 6.5% increase in healthcare spending from 2023 to 2024, slightly higher than the 6.3% rise recorded in 2023. Thus, the continued surge in healthcare expenditure is set to support the expansion of the Charcot-Marie-Tooth disease market.

Leading companies in the Charcot-Marie-Tooth (CMT) disease market are concentrating on developing advanced therapies, such as mesenchymal stem cell treatments, which offer ease of isolation and expansion from various tissue sources. Mesenchymal stem cell therapies utilize versatile cells capable of differentiating into multiple tissue types to promote healing and reduce inflammation in diverse health conditions. For example, in March 2025, ENCell Co. Ltd., a South Korea-based biopharmaceutical firm, announced that the U.S. Food and Drug Administration granted orphan drug designation to EN001, a mesenchymal stem cell therapy designed to treat CMT disease. EN001 aims to enhance cell survival and boost the release of therapeutic molecules. Upon administration, the therapy targets nerve repair, stimulates the release of healing factors, and supports nerve remyelination. A phase 1 open-label, dose-escalation clinical trial (NCT05333406) was conducted involving patients with type 1a CMT to evaluate safety, tolerability, and optimal dosing over 16 weeks, following a 3+3 trial design. Participants in the low-dose group received an intravenous dose on the first day.

In November 2024, the Charcot-Marie-Tooth Association (CMTA), a U.S.-based non-profit organization, partnered with the Inherited Neuropathy Consortium (INC) to advance comprehensive research across all variants of Charcot-Marie-Tooth disease. This collaboration aims to accelerate the translation of research into clinical applications, pushing treatments forward and offering hope to individuals affected by Charcot-Marie-Tooth. The Inherited Neuropathy Consortium (INC) is a U.S.-based clinical research consortium focused on rare diseases.

Major players in the charcot-marie-tooth disease market are F-Hoffmann-La-Roche-Ltd, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., Chong Kun Dang Pharmaceutical Corp., Ionis Pharmaceuticals Inc., Ultragenyx Pharmaceutical Inc., Acceleron Pharma, Affectis Pharmaceuticals AG, NMD Pharma, Pharnext SA, MedDay Pharmaceuticals, Inflectis BioScience, Helixmith Co. Ltd., Addex Therapeutics, Augustine Therapeutics, DTx Pharma Inc., ENCell Co.

North America was the largest region in the charcot-marie-tooth disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in charcot-marie-tooth disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the charcot-marie-tooth disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The charcot-marie-tooth disease market consists of revenues earned by entities by providing services such as genetic testing services, physical therapy services, occupational therapy services, and orthotic fitting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The charcot-marie-tooth disease market also includes sales of custom insoles, mobility aids, electrostimulation devices, and compression garments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Charcot-Marie-Tooth Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on charcot-marie-tooth disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for charcot-marie-tooth disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The charcot-marie-tooth disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Charcot-Marie-Tooth Disease Market Characteristics

3. Charcot-Marie-Tooth Disease Market Trends And Strategies

4. Charcot-Marie-Tooth Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Charcot-Marie-Tooth Disease Growth Analysis And Strategic Analysis Framework

6. Charcot-Marie-Tooth Disease Market Segmentation

7. Charcot-Marie-Tooth Disease Market Regional And Country Analysis

8. Asia-Pacific Charcot-Marie-Tooth Disease Market

9. China Charcot-Marie-Tooth Disease Market

10. India Charcot-Marie-Tooth Disease Market

11. Japan Charcot-Marie-Tooth Disease Market

12. Australia Charcot-Marie-Tooth Disease Market

13. Indonesia Charcot-Marie-Tooth Disease Market

14. South Korea Charcot-Marie-Tooth Disease Market

15. Western Europe Charcot-Marie-Tooth Disease Market

16. UK Charcot-Marie-Tooth Disease Market

17. Germany Charcot-Marie-Tooth Disease Market

18. France Charcot-Marie-Tooth Disease Market

19. Italy Charcot-Marie-Tooth Disease Market

20. Spain Charcot-Marie-Tooth Disease Market

21. Eastern Europe Charcot-Marie-Tooth Disease Market

22. Russia Charcot-Marie-Tooth Disease Market

23. North America Charcot-Marie-Tooth Disease Market

24. USA Charcot-Marie-Tooth Disease Market

25. Canada Charcot-Marie-Tooth Disease Market

26. South America Charcot-Marie-Tooth Disease Market

27. Brazil Charcot-Marie-Tooth Disease Market

28. Middle East Charcot-Marie-Tooth Disease Market

29. Africa Charcot-Marie-Tooth Disease Market

30. Charcot-Marie-Tooth Disease Market Competitive Landscape And Company Profiles

31. Charcot-Marie-Tooth Disease Market Other Major And Innovative Companies

32. Global Charcot-Marie-Tooth Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Charcot-Marie-Tooth Disease Market

34. Recent Developments In The Charcot-Marie-Tooth Disease Market

35. Charcot-Marie-Tooth Disease Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â